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Allergic aspergillosis is a Th2 T-lymphocyte-mediated pulmonary complication in patients with atopic
asthma and cystic fibrosis. Therefore, any therapeutic strategy that selectively inhibits Th2 T-cell activation
may be useful in downregulating allergic lung inflammation in asthma. In the present study, we developed a
CpG oligodeoxynucleotide (ODN)-based immune intervention of allergic inflammation in a mouse model of
allergic aspergillosis. Four different groups of mice were used in a short-term immunization protocol. Three
experimental groups of animals (groups 1 to 3) were sensitized with Aspergillus fumigatus antigens. Animals in
group 1 were immunized with A. fumigatus antigen alone, while those in group 2 were treated with CpG–ODN
1 day before the first antigen immunization, and the animals in group 3 received the first CpG–ODN
administration between the antigen treatments. The animals in group 4 served as controls and were given
phosphate-buffered saline. Allergen-specific serum immunoglobulins and total immunoglobulin E in
different groups of animals were measured by enzyme-linked immunosorbent assay, while airway remod-
eling and cytokine production were studied by immunohistochemistry. The results demonstrated that
CpG–ODN administration either before (group 2) or between (group 3) antigen treatments resulted in
reduced total immunoglobulin E levels and peripheral blood eosinophil numbers compared to A. fumigatus
allergen-sensitized group 1 animals. Similarly, treatment with CpG–ODN also downregulated inflamma-
tory cell infiltration, goblet cell hyperplasia, and basement membrane thickening compared to A. fumiga-
tus-sensitized mice. The distinct reduction in peripheral blood eosinophilia and airway remodeling in
CpG–ODN-treated mice emphasized its usefulness as an immunomodulating agent for allergic fungal
diseases.
Allergic asthma is characterized by airway eosinophilia,
bronchial hyperresponsiveness, and airway remodeling, with an
underlying disease mechanism mainly orchestrated by CD4
Th2 T lymphocytes. The rising incidence of asthma, with more
than 130 million people affected in Western countries alone,
creates an urgent need for effective treatment and therapeutic
strategies (17).
Allergen-specific immunoglobulin E (IgE) plays an impor-
tant role in eosinophil recruitment during the late-phase reac-
tion. Interleukin-4 (IL-4), the major Th2 cytokine involved in
differentiation and activation, is also secreted by several non-
T-helper cells, including mast cells and NK cells. The early
production of IL-4 from these cellular sources may trigger Th2
cell differentiation, resulting in a predominantly allergic phe-
notype. In contrast, Th1 cells produce the cytokine gamma
interferon (IFN-), which downregulates IL-4 and inhibits al-
lergic responses (6). Considerable evidence accumulated in the
literature also indicates that eosinophils play a key role in
mediating injury to the bronchial mucosa (3).
Recent studies have shown that IL-12 and IFN- inhibit
allergen-induced Th2 cytokine expression, IgE synthesis, eo-
sinophil recruitment, and airway remodeling in murine models
of asthma (20, 21). Among various strategies that have been
attempted for immunomodulation of allergic reactions, immu-
nization with nonmethylated CpG oligodeoxynucleotides
(ODN) holds promise to induce the innate immune system and
produce a variety of Th1-associated cytokines, predominantly
IFN- and IL-12 from monocytes and NK cells (4). In animal
models of asthma induced by ovalbumin, Schistosoma mansoni,
and ragweed, CpG–ODN administration reduce the allergen
responses with a significant reduction in lung and blood eosin-
ophilia and allergen-specific serum IgE levels (2, 4, 22).
Allergic aspergillosis is caused by exposure to A. fumigatus
antigens from the environment and the proteins and toxins
from inhaled fungal spores complicate asthma and result in
immunologic lung destruction (11, 12). The disease is charac-
terized by high serum total IgE, A. fumigatus-specific IgE, and
peripheral blood eosinophilia and central bronchiectasis (3, 8,
11). In children, allergic aspergillosis could be the cause of
recurrent pneumonia and may increase the severity of asthma,
and in cystic fibrosis patients, fungal colonization may worsen
the course of disease and prognosis (3, 18).
The murine models of allergic aspergillosis provide valuable
information on the immunopathogenesis of fungal allergy with
major involvement of Th2 cytokines, IgE, and eosinophils in
the development of the disease (9, 14). Hence, in the search for
an alternative immunomodulation strategy, we attempted to
* Corresponding author. Mailing address: VA Medical Center, Re-
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develop a CpG–ODN-based immune intervention in a mouse
model of allergic aspergillosis.
MATERIALS AND METHODS
Synthesis of ODN. CpG–ODN GCTAGACGTTAGCGT, containing unmeth-
ylated CpG, oligodeoxynucleotides (ODNs), and methylated oligonucleotide
without the CpG motif (M-ODN) (5-TGACTGTGAAGGTTAGAGATCA-3)
were synthesized by TriLink Biotechnologies (San Diego, Calif.). The phosphate
backbone of the oligonucleotide was modified to a phosphorothioate group to
impart nuclease resistance and hence prevent degradation when used in the in
vivo studies. The modified oligonucleotide was purified by high-pressure liquid
chromatography (2). These CpG–ODNs had undetectable lipopolysaccharides
for their endotoxin levels when tested by the Limulus amebocyte assay (Bio-
Whittaker, Walkersville, Md.).
Induction of allergic airway inflammation. Six- to 8-week-old female BALB/c
mice were purchased from Charles River laboratories (Wilmington, Mass.). Four
different groups of animals with five mice in each group were used in this study.
The immunization protocol is given in Table 1. Three intraperitoneal injections
were given at 3-day intervals with doses of 100 g of A. fumigatus culture filtrate
extract in phosphate-buffered saline (PBS) mixed with 1 mg of alum (Sigma).
Following the intraperitoneal injections, the animals in all three groups were
given three intranasal challenges with 50 g of A. fumigatus antigen in PBS. As
shown in Table 1, the animals belonging to groups 2 and 3 also received injec-
tions of CpG–ODN intraperitoneally or intranazsally (50 g in PBS/mouse). The
control mice in group 4 received only PBS instead of antigen or CpG.
Determination of A. fumigatus-specific antibodies in serum and bronchoalveo-
lar lavage fluid samples. A. fumigatus-specific IgG1, IgG2a, and IgG2b levels in
the sera and bronchoalveolar lavage fluids of mice were measured by enzyme-
linked immunosorbent assay (9). Bronchoalveolar lavage fluid was collected from
each animal by injecting 1 ml of cold Ca2-, Mg2-, and pyrogen-free PBS with
0.1% EDTA through the trachea with an 18-gauge catheter into the lung, and the
fluid was slowly withdrawn with an attached syringe. The process was repeated
one more time, and the total fluid was pooled. The collected lavage samples were
centrifuged at 1,200 rpm for 5 min, and the protein concentration in the super-
natants was estimated by the bicinchoninic acid method. The supernatants were
aliquoted and kept at 20°C for future use. Microtiter plates were coated with
A. fumigatus antigens (5 g/ml) and kept overnight at 4°C. Serum (1:50, vol/vol)
and bronchoalveolar lavage fluid (undiluted) were added to the plate and incu-
bated for 3 h at room temperature. The addition of secondary antibody and color
development were carried out as described earlier (14).
Estimation of total IgE in serum samples. The total IgE in the serum samples
was measured by enzyme-linked immunosorbent assay with a rat anti-mouse
monoclonal antibody as previously reported (10, 14). The serum IgE levels were
expressed as nanograms per milliliter of serum with a standard curve.
Lung histology. The lungs were infused with 1 ml of sterile PBS and fixed in
10% neutral buffered formalin. The tissues were processed and embedded in
paraffin, and sections were cut at a thickness of 5 m and stained with hema-
toxylin and eosin, periodic acid Schiff base, and Trichrome Masson stains and
evaluated microscopically (10). Morphological changes evaluated included
perivascular and peribronchial inflammation and infiltration of eosinophils, lym-
FIG. 1. Effect of CpG–ODN on A. fumigatus-specific IgG1, IgG 2a, and IgG2b in the sera of different groups of animals. Bars represent mean
optical density values (mean standard error) from five mice in each group studied by enzyme-linked immunosorbent assay. The immunoglobulin
levels in pre- and postimmunization serum samples are presented for group 1, group 2, group 3, and group 4 from left to right within each grouping.
The asterisk (*) indicates a statistically significant difference in immunoglobulin levels between A. fumigatus-sensitized group 1 and CpG-treated
group 2 and group 3 mice (P  0.05).
TABLE 1. Immunization schedule for CpG-mediated immune




Group 1 Group 2 Group 3 Group 4
1 (IP) CpG
1 (IP) Antigen Antigen Antigen PBS
4 (IP) Antigen Antigen Antigen PBS
7 (IP) Antigen Antigen Antigen PBS
8 (IP) CpG CpG
10 (IN) Antigen Antigen Antigen PBS
11 (IN) CpG CpG
13 (IN) Antigen Antigen Antigen PBS
14 (IN) CpG CpG
17 (IN) Antigen Antigen Antigen PBS
18 Sacrificed Sacrificed Sacrificed Sacrificed
a IP, intraperitoneal; IN, intranasal.












phocytes, macrophages, neutrophils, and plasma cells. Perivascular and peribron-
chial eosinophil infiltration was graded as none to severe on a 0 to 4 scale as
described previously (9, 10, 23).
Eosinophil staining of the blood. Eosinophils were evaluated in blood samples
collected from the heart at the time of sacrifice as described earlier (23).
EPO staining of lung sections. Lung tissues embedded in tissue freezing
medium (Polysciences, Inc.) were cryosectioned at 10 m and fixed onto poly-
L-lysine-coated slides. Lung eosinophil infiltration was studied by microscopic
examination after staining for eosinophil peroxidase with DAB (3,3-diaminoben-
zidine tetrahydrochloride; Sigma). The sections were incubated initially with 10
mM cyanide buffer and rinsed in PBS, followed by incubation with peroxidase
substrate and DAB for 10 min at room temperature. The slides were rinsed
thoroughly with water and examined under a light microscope. The number of
eosinophil peroxidase (EPO)-positive cells in each lung section was counted
from five different microscopic fields. The average total cells from each of five
mice belonging to groups 1 and 2 were enumerated and compared.
IL-4, IL-5, and IFN- staining of the lung sections. Lung sections were fixed
with 4% paraformaldehyde after rinsing with PBS. The slides were then incu-
bated in 0.3% H2O2 in PBS for 15 min. After washing three times with PBS for
5 min each, sections were blocked with PBS containing 5% bovine serum albu-
min for 3 h. The sections were then incubated with a 1:20 dilution of biotinylated
anticytokine antibodies (Pierce Chemical; Rockford, Ill.) in PBS containing 3%
bovine serum albumin for 2 h at room temperature. Streptavidin-peroxidase
(1:50) was added, and the slides were incubated for 30 min at room temperature.
The color was developed with DAB substrate as mentioned above. The number
of cytokine-positive cells in each lung section was counted as described above for
EPO.
Statistics. The mean serum antibody levels, total serum IgE, and eosinophil
numbers from different groups of mice were compared by one-way analysis of
variance. The differences between group 1 and the other groups were compared
with Dunnett’s post hoc test, and a P of 0.05 was considered statistically
significant.
RESULTS
Effects of CpG–ODN administration on A. fumigatus-spe-
cific immunoglobulin levels in sera and bronchoalveolar la-
vage fluids. In an attempt to develop an immunomodulatory
intervention for Th2 cytokine-mediated hypersensitivity re-
sponses, we examined CpG–ODN administration at different
time points during A. fumigatus-induced development of aller-
gic lung inflammation (Table 1). The antibody response in the
different groups of mice is shown in Fig. 1. A. fumigatus-specific
IgG2a antibody levels in serum samples from group 2 mice who
had received CpG–ODN before antigen sensitization were
higher compared with A. fumigatus-immunized mice in group
1, and the post hoc test revealed that the difference was sta-
tistically significant (P  0.022). The IgG2b values for groups
2 and 3 were significantly higher in comparison with the values
for group 1 animals, with P  0.02. On the other hand, CpG–
ODN administration either before (group 2) or between
(group 3) allergen administrations failed to show statistically
significant differences in A. fumigatus-specific IgG1 levels
among groups 1, 2, and 3. All control animals showed only
normal levels of IgG antibodies. There was a trend towards an
increase in A. fumigatus-specific IgG2a in bronchoalveolar la-
vage fluids of group 2 animals (data not shown) following two
intranasal CpG–ODN instillations between the allergen chal-
lenges, although the difference was not statistically significant.
CpG–ODN downregulates total IgE in the sera of CpG-
treated mice. There was a 7- to 12-fold increase in total IgE
levels in sera from A. fumigatus-sensitized (group 1) and CpG–
ODN-treated (groups 2 and 3) animals compared to PBS-
treated control group 4 (Fig. 2A). However, CpG-treated
groups 2 and 3 exhibited a significant reduction in total IgE in
sera compared to A. fumigatus-sensitized group 1, and post hoc
analysis showed that the differences were statistically signifi-
cant at P  0.05 for both groups compared to group 1.
Effect of CpG–ODN on peripheral blood eosinophil num-
bers. Peripheral blood eosinophil counts among all groups
were significantly different (P  0.001), with blood eosinophil
counts for group 1 to be significantly higher than group 2,
group 3, and group 4, with mean differences of 92  12, 80 
12, and 98  14, respectively (Fig. 2B).
CpG–ODN downregulate the expression of IL-4 and IL-5 in
airways of A. fumigatus-sensitized and -challenged mice. To
investigate the potential immunomodulatory mechanism re-
sponsible for the CpG–ODN-induced Th1 responses over the
existing Th2 responses in A. fumigatus-sensitized mice, we ex-
amined the expression of IFN--, IL-4-, and IL-5-secreting
cells in lung sections from A. fumigatus-sensitized (group 1)
and CpG–ODN-treated (group 2) animals (Fig. 3). Immuno-
staining of the lung sections with anticytokine antibodies re-
vealed a significant reduction in IL-4- and IL-5-producing cells
(	90%) in CpG–ODN-treated animals (Fig. 3A and C) com-
pared with an A. fumigatus-sensitized animals (Fig. 3B and D).
A predominantly Th1 type immune response in vaccinated
animals was also evidenced by an increase in the number of
FIG. 2. (A) Total serum IgE in A. fumigatus-sensitized and CpG–
ODN-treated mice. Bars represent mean optical values (mean  stan-
dard error). The asterisk (*) indicates a statistically significant differ-
ence in total IgE levels among A. fumigatus-sensitized group 1 and
CpG-treated group 2 and group 3 mice (P  0.05). (B) Eosinophils in
the peripheral blood of A. fumigatus-sensitized and CpG–ODN-
treated mice. The bars represent mean cell counts (mean  standard
error) in samples from five mice in each group. The asterisk (*)
represents a statistically significant difference between A. fumigatus-
sensitized group 1 and CpG-treated group 2 and group 3 (P  0.001).












FIG. 3. Immunomodulatory effects of CpG–ODN treatment in lung sections of A. fumigatus-sensitized and CpG–ODN-treated mice (magni-
fications, 
60). (A) IL-4-expressing cells in the lung section of a CpG-treated (group 2) mouse. (B) IL-4-expressing cells in the lung section of an
A. fumigatus-sensitized mouse with no CpG treatment (group 1). The arrow indicates the cytokine-expressing cells. (C) IL-5-expressing cells in the
lung section of a group 2 animal. (D) IL-5-expressing cells in the lung section of a group 1 animal. The arrow indicates IL-5-expressing cells.
(E) IFN--expressing cells on the lung section of a group 2 animal. The arrow indicates IFN--producing cells. (F) IFN- staining of the lung
section from a group 1 mouse. (G) Eosinophil peroxidase staining of the lung section from a CpG-treated group 2 animal. (H) Eosinophil
peroxidase staining of the lung section from a group 1 animal. (I) The number of IL-4-, IL-5-, IFN--, and EPO-positive cells in lung sections
enumerated quantitatively. Results are represented as mean standard error (for details, see Materials and Methods). The asterisk (*) represents
a statistically significant difference in cytokine- and EPO-positive cells in lung sections from A. fumigatus-sensitized and CpG-treated mice (P 
0.001).












IFN--producing cells (Fig. 3E) compared with A. fumigatus-
treated animals in group 1 (Fig. 3F). Cells-expressing IL-4,
IL-5, and IFN- were enumerated and compared among the
different groups and are shown in Fig. 3I. There was a marked
reduction of cells-expressing IL-4 and IL-5 but an increase in
IFN--secreting cells in the CpG-treated group compared to
the group treated with A. fumigatus alone. In all these cases, P
was less than 0.001.
CpG–ODN inhibit A. fumigatus-induced airway and lung
eosinophilia. Examination of eosinophil infiltration in the
lungs by eosinophil peroxidase staining of lung sections indi-
cates a significant increase in eosinophil numbers in A. fumiga-
tus-sensitized and A. fumigatus-challenged mice (group 1) com-
pared with DNA-treated mice (Fig. 3G). Even with the high
doses of the A. fumigatus sensitization protocol (100 g/immu-
nization) used in this study, CpG–ODN significantly inhibited
eosinophil recruitment in the lung and peripheral blood of
treated groups (Fig. 3H). EPO-positive cells in the lung
showed significant reductions (P  0.001) in their numbers in
CpG-treated mice compared to mice treated with Aspergillus
organisms alone (Fig. 3I).
CpG–ODN restricts inflammatory cell infiltration in air-
ways. Histopathological analysis of the airways of mice sensi-
tized and challenged with A. fumigatus demonstrated chronic
interstitial infiltration with lymphocytes, a small number of
plasma cells, epithelioid histiocytes, neutrophils,and a large
number of eosinophils (Fig. 4B). The bronchioles were sur-
rounded by chronic inflammatory infiltrates and were fre-
quently lined with a hyperplastic epithelium. Under higher
magnification, the majority of the infiltrating cells were iden-
tified as eosinophils (a grade of 4), and a severe bronchial
epithelial hyperplasia was noticed throughout the lung section
(Fig. 4D). Although there was cellular infiltration in the lung
section from CpG-treated mice, we noticed a marked reduc-
tion in eosinophils from grade 4 to grade 1 around the small
bronchi and blood vessels and also less damage to the bron-
chial epithelial lining (Fig. 4A and C).
CpG–ODN downregulates mucus glycoprotein production
and basement membrane thickening in A. fumigatus-sensitized
mice. Airway remodeling in chronic asthma is also character-
ized by significant mucopolysaccharide secretion and airway
goblet cell hyperplasia. CpG–ODN administration, 24 h before
the A. fumigatus sensitization and challenge (group 2) exhib-
ited a significant reduction in the secretion of mucous glyco-
protein (Fig. 4E, G) compared to A. fumigatus-sensitized mice
(Fig. 4F, H). The thickness of the subepithelial collagen layer
was evaluated in A. fumigatus immunized and CpG–ODN-
vaccinated mice with Trichrome Masson stain. Immunomodu-
lation in CpG–ODN-vaccinated mice was evident by a de-
crease in submucosal collagen deposition in airways (Fig. 4I)
compared to that in the airways from A. fumigatus-immunized
mice (Fig. 4J).
DISCUSSION
Allergic aspergillosis is caused by exposure to A. fumigatus
spores from the environment and the immunologic lung de-
struction is largely due to fungal colonization of the respiratory
tree and the result of immunologic inflammatory response of
the host to the fungal antigens (11). Inflammatory responses of
the airways are characterized by cellular infiltration of eosin-
ophils and T lymphocytes expressing Th2 cytokines as well as
extensive airway remodeling (9, 14, 15). Recent studies have
shown that bacterial DNA carrying non methylated CpG mo-
tifs can be used as vaccine adjuvant to selectively induce Th1-
dominated immune responses and therefore might be useful as
an immunomodulatory agents to treat or prevent undesired
FIG. 3—Continued.












FIG. 4. Lungs from A. fumigatus-sensitized (group 1) and CpG–ODN -treated (group 2) mice were fixed in 10% buffered formalin, embedded
in paraffin, sectioned, and stained with hematoxylin and eosin, periodic acid-Schiff base, and Trichrome. (A) Hematoxylin and eosin staining of
group 2 lung sections, showing moderate inflammatory infiltrates adjacent to bronchioles and small blood vessels without eosinophil infiltrations
(magnifications, 
60), (B) Hematoxylin and eosin staining of a lung section from a group 1 animal showing extensive peribronchaeolar and
perivascular inflammation. The bronchial epithelium is hyperplastic (
60). (C) Higher magnification of A (
400). (D) Higher magnification of
B (
400), showing the large number of eosinophils and distinct epithelial hyperplasia. (E) Periodic acid-Schiff staining of the lung section from
a group 2 mouse, showing very few goblet cells around bronchial mucosa. (F) Periodic acid-Schiff staining of the lung section from a group 1 mouse,
showing the large number of mucous glycoconjugate-producing goblet cells in bronchial mucosa. (G and H) Higher magnifications (
400) of E
and F, respectively. (I) Trichrome staining of a section from a group 2 mouse exhibiting less peribronchial collagen deposition (
60). (J) There
was significantly more collagen deposition around the airways of group 1 compared to CpG–ODN-treated animals.












Th2-dominant immune responses, such as in allergic disorders
(5, 7).
This short-term immunization protocol was designed to in-
vestigate various parameters such as the effect of allergen
exposure on overall immune response in mice under the cyto-
kine milieu of Th1 type (group 2). The immunization protocol
applied to group 3 was mainly to evaluate whether an ongoing
Th2 response (as seen in allergen-sensitized patients) could be
converted to a Th1 response with CpG intervention.
Earlier reports have shown that the effect of CpG–ODN on
reducing the number of tissue eosinophils is immediate and
sustained for about a week (2). Both groups 2 and 3 demon-
strated significant reduction in total IgE in serum and periph-
eral blood eosinophils, indicating a deviation of the response
towards a Th1 type. However, this response was pronounced in
group 2 mice receiving systemic CpG–ODN 1 day before the
beginning of allergen sensitization. Similarly, in the present
study, a twofold increase in A. fumigatus-specific IgG2a and
IgG2b as well as significant reduction in IgE levels in the serum
and bronchoalveolar lavage fluid samples of CpG–ODN-
treated mice compared with A. fumigatus-sensitized animals
suggest an antigen-specific Th1 cell recruitment. However, A.
fumigatus-sensitized group 1 and CpG–ODN-treated groups 2
and 3 exhibited comparable allergen-specific IgG1. This find-
ing is in line with our previous results, where anti-IL-4-treated
and IL-4 knockout BALB/c mice produced specific IgG1 anti-
body when exposed to Aspergillus antigen, indicating that IgG1
is not predominantly regulated by IL-4 (13, 15).
Experimental evidence has shown that CpG-induced immu-
nomodulation begins with the activation of the innate immune
response that could initially prevent the development of asth-
matic symptoms by inhibiting early eosinophil accumulation
and later even bias the ongoing immune response to produce
an antigen-specific Th1 microenvironment in the host encoun-
tering subsequent antigen exposures (19, 22). In a murine
model of invasive pulmonary aspergillosis, local delivery of
CpG–ODN and a recombinant A. fumigatus allergen resulted
in functional maturation and activation of airway dendritic
cells towards a Th1 immune response and resistance to the
fungus (1). Another recent study demonstrated that when mice
primed with CpG–ODN-treated dendritic cells, a marked de-
pletion of CD4 CD25 Treg cells resulting in enhancement of
IFN- producing cells and downregulation of IL-4 production
in lymph node cells (16). Indeed, in the present mouse model
of allergic aspergillosis, CpG administration resulted in a sig-
nificant reduction in eosinophil recruitment in the lung, indi-
cating a persistent Th1 response.
In order to investigate the effect of intranasal CpG admin-
istration in airways, we carried out immunostaining for IL-4-,
IL-5-, and IFN--secreting cells in the A. fumigatus-sensitized
(group 1) and CpG-vaccinated (group 2) animals. CpG-vacci-
nated animals had a significant reduction in IL-4-secreting cells
in the airways compared to airways from A. fumigatus-sensi-
tized mice. The presence of IFN--producing cells in the CpG-
treated airways may be instrumental in augmenting a predom-
inant Th1 response associated with the corresponding
reduction of IL-4-producing cells and a reduced Th2 response
(6). The ability of CpG to reduce IL-5 cytokine secretion in the
lung compartment can be correlated with a marked reduction
in airway eosinophilic infiltration in CpG-treated mice. Taken
together, the overall immune responses in CpG–ODN-treated
mice in this study show results comparable to those of other
studies, where administration of anti-IL-4, anti-IL-5, IFN-,
and IL-12 inhibited allergic lung inflammation in mouse mod-
els of asthma (19). In this context, the use of CpG–ODN for
the treatment of respiratory complication due to fungal aller-
gens may be more advantageous than administration of exog-
enous cytokines because endogenously produced cytokines by
CpG–ODN are likely to follow a regulatory mechanism and
thereby may cause less toxicity than exogenously administered
cytokines.
In allergic aspergillosis, the inhaled fungal spores are
trapped in the tenacious mucus in patients’ large segmental
bronchi, germinate, and form hyphae, and the immune reac-
tions and proteolytic enzymes generated by A. fumigatus cause
pulmonary infiltrates, tissue damage, and eventually central
bronchiectasis (3, 12). In this study, the A. fumigatus-sensitized
animals in group 1 showed similar airway remodeling with
peribronchial and perivascular infiltration and accumulation of
a large number of eosinophils, goblet cell hyperplasia, and
basement membrane thickening. A significant reduction in air-
way eosinophilia, mucus secretion, and collagen deposition in
the airways of CpG-treated mice strongly suggest a possible
immune intervention by DNA vaccination in combating the
airway remodeling in patients with complication of allergic
aspergillosis.
In conclusion, we report CpG–ODN-mediated immune in-
tervention via the systemic and mucosal routes in a murine
model of allergic aspergillosis. A significant increase in A.
fumigatus-specific Th1 responses and distinct reduction in pul-
monary eosinophilia and airway remodeling in animals receiv-
ing CpG–ODN prophylactically compared with the A. fumiga-
tus-sensitized mice emphasize the usefulness of DNA-
mediated intervention in allergic diseases. Hence, CpG–ODN
may be explored as an immunomodulating agent for fungus-
induced inflammation in patients with allergic aspergillosis.
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